Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17340395 | 0.83 | ALDH1A1 (1.00) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL2919412 | 0.80 | ALDH1A1 (0.73) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL17340394 | 0.80 | ALDH1A1 (0.81) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL20142740 | 0.79 | ALDH1A1 (0.73) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL2918809 | 0.78 | ALDH1A1 (0.70) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL12087991 | 0.78 | ALDH1A1 (0.65) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL12266478 | 0.78 | PDE4D (0.73) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL29838942 | 0.78 | ALDH1A1 (0.63) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL8422338 | 0.77 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 | |
| SCHEMBL23400296 | 0.76 | CYP2C9 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378255-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20240182478-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION | 2024-06-06 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220298162-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-09-22 | — | — | US | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3538513-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | Dynavax Technologies Corporation (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089695-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089695-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298162-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | ALDH1A1 3948/4885CYP3A4 4296/4885CYP2C9 3719/4885 |
| US-20240182478-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | ALDH1A1 3948/4885CYP3A4 4296/4885CYP2C9 3719/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | ALDH1A1 3948/4885CYP3A4 4296/4885CYP2C9 3719/4885 |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | ALDH1A1 3948/4885CYP3A4 4296/4885CYP2C9 3719/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | ALDH1A1 4038/4885CYP3A4 4485/4885CYP2C9 3522/4885 |
| US-12378255-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | ALDH1A1 3948/4885CYP3A4 4296/4885CYP2C9 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.